
News|Articles|November 1, 2002
From the ESC Congress: Combination therapy improves LV remodeling in CHF better than monotherapy
Patients with mild chronic heart failure who are treated early on with the beta blocker carvedilol (Coreg) along with the angiotensin-converting enzyme (ACE) inhibitor enalapril demonstrated a significantly greater improvement in left ventricular remodeling than patients receiving either drug alone, according to a 572-patient study presented at the European Society of Cardiology (ESC) Congress in September in Berlin. The results reinforce current treatment recommendations.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
Prior authorization isn’t shrinking. Its savings are
5





















